Fresenius Medical Care AG & Co. KGaA (NYSE:FMS) Rating Increased to Strong-Buy at Wall Street Zen

Wall Street Zen upgraded shares of Fresenius Medical Care AG & Co. KGaA (NYSE:FMS) from a buy rating to a strong-buy rating in a research note published on Saturday.

Several other research firms have also commented on FMS. Jefferies Financial Group lowered Fresenius Medical Care AG & Co. KGaA from a “moderate sell” rating to a “strong sell” rating in a research report on Tuesday, February 24th. Truist Financial set a $28.00 price target on Fresenius Medical Care AG & Co. KGaA in a research report on Monday, January 5th. Morgan Stanley restated an “underweight” rating on shares of Fresenius Medical Care AG & Co. KGaA in a research report on Tuesday, January 27th. Erste Group Bank lowered Fresenius Medical Care AG & Co. KGaA from a “strong-buy” rating to a “hold” rating in a research report on Thursday, February 5th. Finally, The Goldman Sachs Group lowered Fresenius Medical Care AG & Co. KGaA from a “buy” rating to a “neutral” rating in a research report on Tuesday, January 20th. Five equities research analysts have rated the stock with a Hold rating and four have assigned a Sell rating to the stock. Based on data from MarketBeat, Fresenius Medical Care AG & Co. KGaA currently has a consensus rating of “Reduce” and a consensus target price of $28.00.

Fresenius Medical Care AG & Co. KGaA Trading Up 2.9%

Shares of Fresenius Medical Care AG & Co. KGaA stock opened at $23.43 on Friday. The firm has a market capitalization of $13.08 billion, a price-to-earnings ratio of 12.26, a PEG ratio of 2.15 and a beta of 0.89. Fresenius Medical Care AG & Co. KGaA has a fifty-two week low of $20.94 and a fifty-two week high of $30.46. The company has a debt-to-equity ratio of 0.40, a quick ratio of 0.92 and a current ratio of 1.26. The stock has a 50 day moving average of $23.13 and a 200 day moving average of $23.85.

Fresenius Medical Care AG & Co. KGaA (NYSE:FMS) last issued its quarterly earnings data on Saturday, February 14th. The company reported $1.69 earnings per share for the quarter. Fresenius Medical Care AG & Co. KGaA had a return on equity of 8.73% and a net margin of 5.03%.The company had revenue of $5.95 billion during the quarter. As a group, research analysts predict that Fresenius Medical Care AG & Co. KGaA will post 1.51 earnings per share for the current year.

Institutional Trading of Fresenius Medical Care AG & Co. KGaA

A number of hedge funds and other institutional investors have recently bought and sold shares of FMS. Morgan Stanley raised its stake in Fresenius Medical Care AG & Co. KGaA by 47.2% in the fourth quarter. Morgan Stanley now owns 2,939,839 shares of the company’s stock valued at $70,027,000 after buying an additional 942,497 shares in the last quarter. Bank of America Corp DE raised its stake in Fresenius Medical Care AG & Co. KGaA by 279.7% in the second quarter. Bank of America Corp DE now owns 337,316 shares of the company’s stock valued at $9,637,000 after buying an additional 248,477 shares in the last quarter. ABC Arbitrage SA raised its stake in Fresenius Medical Care AG & Co. KGaA by 1,136.0% in the fourth quarter. ABC Arbitrage SA now owns 249,800 shares of the company’s stock valued at $5,950,000 after buying an additional 229,589 shares in the last quarter. Integral Health Asset Management LLC raised its stake in Fresenius Medical Care AG & Co. KGaA by 44.4% in the fourth quarter. Integral Health Asset Management LLC now owns 650,000 shares of the company’s stock valued at $15,483,000 after buying an additional 200,000 shares in the last quarter. Finally, Pzena Investment Management LLC raised its stake in Fresenius Medical Care AG & Co. KGaA by 1.0% in the third quarter. Pzena Investment Management LLC now owns 14,816,852 shares of the company’s stock valued at $390,128,000 after buying an additional 153,870 shares in the last quarter. 8.37% of the stock is currently owned by institutional investors and hedge funds.

About Fresenius Medical Care AG & Co. KGaA

Fresenius Medical Care AG & Co KGaA is the world’s largest integrated provider of products and services for individuals with renal diseases. The company’s primary business activities encompass the operation of dialysis clinics and the manufacture and distribution of dialysis equipment, dialysis machines, dialyzers, consumables and related therapies. Through its global network of clinics, Fresenius Medical Care delivers comprehensive kidney care, including hemodialysis and peritoneal dialysis treatments, patient education and support services.

In its products segment, the company designs and produces dialysis machines, water treatment systems and disposables such as high‐flux dialyzers and bloodlines.